2137 Stock Overview
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases.
Brii Biosciences Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$7.91|
|52 Week High||HK$48.65|
|52 Week Low||HK$4.70|
|1 Month Change||41.25%|
|3 Month Change||2.20%|
|1 Year Change||-83.47%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-65.53%|
Recent News & Updates
|2137||HK Biotechs||HK Market|
Return vs Industry: 2137 underperformed the Hong Kong Biotechs industry which returned -52% over the past year.
Return vs Market: 2137 underperformed the Hong Kong Market which returned -24.6% over the past year.
|2137 Average Weekly Movement||16.1%|
|Biotechs Industry Average Movement||11.3%|
|Market Average Movement||8.0%|
|10% most volatile stocks in HK Market||15.0%|
|10% least volatile stocks in HK Market||3.9%|
Stable Share Price: 2137 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: 2137's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria.
Brii Biosciences Limited Fundamentals Summary
|2137 fundamental statistics|
Is 2137 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2137 income statement (TTM)|
|Cost of Revenue||CN¥0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.14|
|Net Profit Margin||-2,084.15%|
How did 2137 perform over the long term?See historical performance and comparison